Cell And Gene Therapy (CGT) Scheduling Software Market Explained: What Is Fueling Growth To $0.8 Billion By 2030?
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Cell And Gene Therapy (CGT) Scheduling Software Market Size, Value And Growth Trajectory Through 2030
The cell and gene therapy (CGT) scheduling software market size has experienced rapid expansion in recent years. It is projected to increase from $0.32 billion in 2025 to $0.39 billion in 2026, at a compound annual growth rate (CAGR) of 19.5%. The historical growth of this market can be attributed to the rising development of cell and gene therapies, the integration of digital scheduling tools into clinical workflows, an increasing emphasis on patient-centric treatment planning, stricter regulatory requirements for CGT tracking, and the expansion of biotechnology infrastructure.
The cell and gene therapy (CGT) scheduling software market is projected for significant expansion over the coming years, reaching $0.8 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 19.7%. This anticipated growth during the forecast period stems from factors such as the increasing deployment of AI-powered scheduling platforms, enhanced integration with cloud-based CGT systems, a heightened need for automated workflow and resource management, the broadening scope of tissue engineering applications, and the escalating requirement for predictive analytics in therapy delivery. Key trends anticipated within this period involve the greater uptake of cloud-based CGT scheduling software, an increasing call for integrated workflow management solutions, a sharpened emphasis on real-time supply chain synchronization, the proliferation of regulatory compliance and reporting instruments, and a growing implementation of training and support offerings.
Get A Free Sample Report With In-Depth Market Insights:
Cell And Gene Therapy (CGT) Scheduling Software Market Growth Momentum: What Factors Are Shaping Demand?
The increasing need for personalized medical approaches is anticipated to fuel the expansion of the cell and gene therapy (CGT) scheduling software market in the future. Personalized medicine involves healthcare solutions and treatments customized for individual patients, considering their genetic composition, biological markers, and distinct disease traits. This demand is escalating due to progress in genomic technologies and molecular diagnostics, enabling medical professionals to customize treatments based on a patient’s genetic profile, thereby enhancing treatment effectiveness. Cell and gene therapy (CGT) scheduling software improves personalized medicine by simplifying the coordination of manufacturing processes unique to each patient, managing treatment schedules, and optimizing clinical procedures. This ensures that therapy is delivered precisely, promptly, and individually, aligned with each patient’s specific genetic characteristics. For example, data from February 2024, provided by the US-based non-profit Personalized Medicine Coalition, indicated that the Food and Drug Administration cleared 16 novel personalized therapies for rare disease patients in 2023, a significant rise from six in 2022. These approvals included seven drugs for cancer and three for various other conditions. Consequently, the escalating need for personalized medicine is a key impetus behind the growth of the cell and gene therapy (CGT) scheduling software market.
Cell And Gene Therapy (CGT) Scheduling Software Market Segment Outlook: Which Categories Are Growing Fastest?
The cell and gene therapy (CGT) scheduling software market covered in this report is segmented –
1) By Component: Software, Services
2) By Deployment Mode: Cloud-Based, On-Premises
3) By Application: Cell Therapy, Gene Therapy, Tissue Engineering, Other Applications
4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Research Institutes, Hospitals And Clinics, Other End-Users
Subsegments:
1) By Software: Cloud-Based Software, On-Premises Software, Integrated Scheduling Platforms, Workflow Management Software, Supply Chain Coordination Software
2) By Services: Implementation Services, Integration Services, Consulting Services, Training And Support Services, Maintenance Services
Cell And Gene Therapy (CGT) Scheduling Software Market Trends Redefining Industry Growth
Leading companies in the cell and gene therapy (CGT) scheduling software markets are concentrating on creating innovative solutions, such as unified digital orchestration platforms, to simplify intricate therapy scheduling, improve real-time supply chain visibility, and enhance coordination between manufacturers and healthcare providers. These unified digital orchestration platforms are integrated software systems designed to coordinate and automate complex workflows like patient scheduling, manufacturing slots, logistics tracking, and clinical site communication within a single centralized environment. For instance, in November 2025, TrakCel Ltd., a UK-based advanced therapy supply chain technology company, introduced Cell And Gene Therapy (CGT) Gateway, a digital orchestration platform aimed at streamlining access to cell and gene therapies for healthcare providers. This platform is a configurable, cloud-based solution that connects treatment centers, manufacturers, and logistics partners within a single digital ecosystem, facilitating automated referral management, patient onboarding, and scheduling workflows. The platform increases transparency through real-time tracking and milestone notifications, supports regulatory compliance with secure data management features, and reduces administrative burden by digitizing communication and documentation processes. It is engineered to accelerate therapy access, improve coordination among stakeholders, and minimize delays in time-sensitive autologous and allogeneic treatments.
Cell And Gene Therapy (CGT) Scheduling Software Market Top Companies Driving Competitive Growth
Major companies operating in the cell gene therapy (CGT) scheduling software market are market are Siemens AG, Deloitte Touche Tohmatsu Limited, Thermo Fisher Scientific Inc., GE Digital LLC, SAP SE, Rockwell Automation Inc., Dassault Systèmes SE, Infor Inc., Aspen Technology Inc., Azenta Life Sciences, Kinaxis Inc., QAD Inc., Bullhorn Inc., Cryoport Inc., MasterControl Inc., TrakCel Ltd., Bluecrux NV, MangoGem S.A., Title21 Health Solutions Inc, Vineti Inc.
View The Full Cell And Gene Therapy (CGT) Scheduling Software Market Report:
Cell And Gene Therapy (CGT) Scheduling Software Market Global Footprint: Which Region Leads The Industry?
North America was the largest region in the cell and gene therapy (CGT) scheduling software market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy (cgt) scheduling software market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
